NEW YORK (GenomeWeb) – Paradigm today announced a collaboration with Deciphera Pharmaceuticals to predict best responders for Deciphera's kinase inhibitor called altiratinib. 

Paradigm will use its PCDx panel to characterize patient tissue samples in a phase I clinical study of altiratinib in order to determine which patients may be sensitive or resistant to the MET, TIE2, VEGFR2, and TRK (A,B,C) kinase inhibitor. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.

Sponsored by

This webinar is the last in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.